VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...

The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

As a general surgeon, I often see patients who’ve been dealing with stomach issues for a long time, hoping the problem will ...

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...

A ChatGPT-like model can diagnose cancer, assist in selecting treatment options, and predict survival outcomes across various ...

Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide. Researchers have reported on the isolation ...

Eating papaya on an empty stomach can help with weight loss, improve heart health, enhance skin glow, ease constipation, and ...

Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...

Stand Up To Cancer ® (SU2C) today announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, ...

LOS ANGELES – Oct. 15, 2024 – Stand Up To Cancer® (SU2C) today announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including ...